Re: Patients' Preferences for Adjuvant Sorafenib after Resection of Renal Cell Carcinoma in the SORCE Trial: What Makes it Worthwhile?
- PMID: 30412976
- DOI: 10.1016/j.juro.2018.05.103
Re: Patients' Preferences for Adjuvant Sorafenib after Resection of Renal Cell Carcinoma in the SORCE Trial: What Makes it Worthwhile?
Comment on
-
Patients' preferences for adjuvant sorafenib after resection of renal cell carcinoma in the SORCE trial: what makes it worthwhile?Ann Oncol. 2018 Feb 1;29(2):370-376. doi: 10.1093/annonc/mdx715. Ann Oncol. 2018. PMID: 29177440 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical